Efficacy and safety of anlotinib in overall and disease-specific advanced gynecological cancer: A real-world study.

Authors

null

Xinyi Hong

Southeast University, Nanjing, China

Xinyi Hong , Shanhu Qiu , Xia Wu , Sizhen Chen , Xiaoxiang Chen , Bei Zhang , Aiqin He , Ying Zhou , Yun Xu , Jianqing Wang , Yingchun Gao , Xizhong Xu , Li Sun , Yang Zhang , Libing Xiang , Jundong Zhou , Qun Guan , Bingwei Chen , Yang Shen

Organizations

Southeast University, Nanjing, China, Zhongda Hospital, Southeast University, Nanjing, China, Department of Gynecological Oncology, Tumor Hospital Affiliated to Nantong University, Nantong, China, Department of Epidemiology and Biostatistics, School of Public health, Southeast University, Nanjing, China, Jiangsu Cancer Hopital, Nanjing, China, Department of Obstetrics and Gynaecology, Xuzhou Central Hospital, Xuzhou, China, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China, The First Peoples Hospital of Changzhou, Changzhou, China, Department of Obstetrics and Gynecology, The Yancheng Clinical College of Xuzhou Medical University, The First people's Hospital of Yancheng, Yancheng, China, Huai'an First People's Hospital, Huai'an, China, Department of Gynecology,Affiliated Hospital of Jiangnan University, Wuxi, China, Department of Gynecological Oncology, Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao, China, Department of Gynecology,Lianyungang First People's Hospital, Lianyungang, China, Ovarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, ChinaOvarian Cancer Program, Department of Gynecologic Oncology, Zhongshan Hospital, Fudan University, Shanghai, China, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China, Gynecology Department, Jiangsu Province Hospital of Chinese Medicine, Nanjing, China, Department of Epidemiology and Biostatistics, School of Public health, Southeast University, Nanjing, -, China, Department of Obstetrics and Gynaecology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China, China

Research Funding

No funding received
None.

Background: Anlotinib is a novel oral small-molecule multi-target tyrosine kinase inhibitor that has been approved for treating non-small cell lung cancer. However, its efficacy and safety among patients with advanced gynecological cancer. We conducted this study to address this issue in the real-world setting. Methods: Data from patients treated with anlotinib for persistent, recurrent or metastatic gynecological cancer including cervical, endometrial, and ovarian cancer were collected from 17 centers from August 2018. The database lock-time was on March 2022. Anlotinib was administered orally on days 1–14 every 3 weeks until disease progression, severe toxicity occurred, or death. The outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Results: A total of 249 patients were analyzed, with a median follow-up of 14.46 months. The overall ORR and DCR were 28.1% (95% CI 22.6% to 34.1%), and 80.7% (95% CI 75.3% to 85.4%), respectively. Specifically, the ORR varied from 19.7% to 34.4% and the DCR differed from 81.7% to 90.0% in disease-specific advanced gynecological cancer. The median PFS was 6.1 months and ranged from 5.6 to 10.0 months in the overall and disease-specific advanced gynecological cancer, respectively. Larger cumulative dosage of anlotinib (>700 mg) was in general associated with longer PFS in the overall and disease-specific advanced gynecological cancer. The most common adverse event related to anlotinib use was pain/arthralgia (18.3%). Conclusions: In conclusion, anlotinib holds promise in treating patients with advanced gynecological cancer, such as cervical, endometrial, and ovarian cancer, with reasonable efficacy and tolerable safety.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gynecologic Cancer

Track

Gynecologic Cancer

Sub Track

Other Gynecologic Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 5608)

DOI

10.1200/JCO.2023.41.16_suppl.5608

Abstract #

5608

Poster Bd #

303

Abstract Disclosures